MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
41.41
+1.91
+4.84%
After Hours: 42.00 +0.59 +1.42% 16:33 05/24 EDT
OPEN
39.55
PREV CLOSE
39.50
HIGH
42.12
LOW
39.55
VOLUME
1.63M
TURNOVER
0
52 WEEK HIGH
77.32
52 WEEK LOW
39.13
MARKET CAP
7.55B
P/E (TTM)
-15.9049
1D
5D
1M
3M
1Y
5Y
BUZZ-Cancer biotechs jump on data ahead of industry meet
Shares of some cancer drug developers gain as they release data summaries from clinical trials ahead of industry meet. American Society of Clinical Oncology meeting to be held May 31-June 4. Merus NV, Legend Biotech, Corbus Pharmaceuticals jump on data ahead of the event.
Reuters · 1d ago
Jefferies Issues a Buy Rating on Legend Biotech (LEGN)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Merus (MRUS) and Agilon Health (AGL)
TipRanks · 1d ago
Legend Biotech Price Target Cut to $73.00/Share From $86.00 by HC Wainwright & Co.
Dow Jones · 1d ago
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Legend Biotech, Lowers Price Target to $73
Benzinga · 1d ago
LEGEND BIOTECH CORPORATION <LEGN.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $73 FROM $86
Reuters · 1d ago
U.S. RESEARCH ROUNDUP-Deckers Brands, Nvidia, Workday
Wall Street securities analysts revise their ratings and price targets on several companies. Deckers Brands, Nvidia and Workday are among the companies. Barclays raises target price to $1089 from $1026 for Deckers brands. Deutsche Bank raises price target for Nvidia to $1000.
Reuters · 2d ago
More
About LEGN
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.